Treatment-free remission in chronic myeloid leukemia
Date
2023
Authors
Shanmuganathan, N.
Ross, D.M.
Editors
Gill, H.
Kwong, Y.
Kwong, Y.
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Book chapter
Citation
Source details - Title: Pathogenesis and Treatment of Leukemia, 2023 / Gill, H., Kwong, Y. (ed./s), pp.635-647
Statement of Responsibility
Conference Name
Abstract
Over the last decade, a medically supervised trial of tyrosine kinase inhibitor (TKI) discontinuation has become an important option for patients with chronic phase chronic myeloid leukaemia (CML). A successful attempt, termed ‘treatment-free remission’ (TFR), has enabled selected patients to remain off TKI therapy long-term and has now been integrated into international treatment guidelines. Approximately 40–65% of chronic phase CML patients who cease TKI while in sustained deep molecular response will be able to remain off TKI in major molecular response 12 months after drug discontinuation. Consequently, understanding the nuances and complexities of TFR is vital for physicians offering and guiding their patients through a TFR attempt. Within this chapter, we present the data underpinning the TFR strategy, including appropriate patient selection and logistics of molecular monitoring. The potential risks and benefits of a TFR attempt will also be discussed, as well as emerging predictors of a successful TFR attempt which may guide future practice.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2023 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.